A continued saga of Boc5, the first non-peptidic glucagon-like peptide-1 receptor agonist with in vivo activities

Glucagon-like peptide-1 (GLP-1)-based therapy presents a promising option for treating type 2 diabetes. However, there are several limitations relative to the peptidic GLP-1 mimetics currently on the market or under development. This concern has led to a continued interest in the search for non-pept...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: He, Min, Guan, Ni, Gao, Wei-wei, Liu, Qing, Wu, Xiao-yan, Ma, Da-wei, Zhong, Da-fang, Ge, Guang-bo, Li, Chuan, Chen, Xiao-yan, Yang, Ling, Liao, Jia-yu, Wang, Ming-wei
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2012
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4010345/
https://ncbi.nlm.nih.gov/pubmed/22301855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/aps.2011.169
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados